Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.
Sponsor: Pfizer
Listed as NCT00058838, this PHASE3 trial focuses on Parkinson Disease and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia, Aix-en-Provence, France, Albany, United States, Alcalá de Henares, Spain, Angers, France, Antwerp, Belgium, Asheville, United States, Athens, Greece, Atlanta, United States, Baltimore, United States and 103 more location s